An aromatase inhibitor + a CDK4/6 inhibitor is a preferred first-line treatment option to treat patients with metastatic HER2-negative breast cancer who are also postmenopausal, as well as patients who are premenopausal and are also receiving ovarian ablation or suppression.
Steroidal aromatase inactivators, selective ER downregulators, and selective estrogen receptor modulators are all examples of preferred second- and subsequent-line therapy options in this population.
Learn more about the treatment of breast cancer.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Fast Five Quiz: Breast Cancer Treatment - Medscape - Jul 12, 2021.